Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Andreas Matouschek
University of Texas, Austin, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kymera Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The Covered Individual receives monetary payment for consulting services provided to Kymera Therapeutics, Inc., a company developing therapeutics that redirect the ubiquitin proteasome system to degrade disease-causing proteins. The business interests of the company are related to the CI’s research; some of the results or outcomes of the research may be of direct interest to the company.
Development of proteasome adaptors to catalytically deplete specific proteins from cells
We propose to develop a versatile technology platform to rapidly deplete specific proteins from cells by shunting them into the cell's own protein degradation machinery, the ubiquitin proteasome system. The technology is designed to serve as a research tool, for therapeutic target validation, and, in principle, as a molecularly-targeted therapy approach. It is based on chimeric proteasome adaptors, we call degradons, which consist of two parts: (i) a recognition element composed of an affinity domain evolved or designed to bind to an oncogenic target, and (ii) a proteasome-binding carrier element, which feeds the target directly into the degradation machinery.
Filed on February 14, 2019.
Tell us what you know about Andreas Matouschek's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Andreas Matouschek filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Andreas Matouschek | University of Texas, Austin | Conflict of Interest | Kymera Therapeutics | $5,000 - $9,999 |
Other search results for: “Andreas Matouschek”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Andreas Matouschek | University of Texas, Austin | Financial Disclosure | Kymera Therapeutics, Inc. |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.